{"id":551539,"date":"2021-07-06T19:10:01","date_gmt":"2021-07-06T19:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=551539"},"modified":"2021-07-06T19:10:01","modified_gmt":"2021-07-06T19:10:01","slug":"schizophrenia-pipeline-possesses-potential-drugs-in-mid-stage-developments-to-be-launched-in-the-upcoming-years","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/schizophrenia-pipeline-possesses-potential-drugs-in-mid-stage-developments-to-be-launched-in-the-upcoming-years_551539.html","title":{"rendered":"Schizophrenia pipeline possesses potential drugs in mid stage developments to be launched in the upcoming years"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1625559442.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Schizophrenia pipeline possesses potential drugs in mid stage developments to be launched in the upcoming years\" src=\"https:\/\/www.abnewswire.com\/uploads\/1625559442.png\" alt=\"Schizophrenia pipeline possesses potential drugs in mid stage developments to be launched in the upcoming years\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Schizophrenia Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The growing prevalence of Schizophrenia patients in the 7MM market has resulted in an increase in Schizophrenia market size.\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/7c0a0801d4d08a3ed622c9db4d8d2f46.jpg\" alt=\"\" \/><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight&rsquo;s <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/schizophrenia-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Schizophrenia market report<\/a><\/strong><span> provides an in-depth understanding of Schizophrenia, historical and forecasted epidemiology, and Schizophrenia market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the Crucial Highlights from the Schizophrenia Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>As per DelveInsight Schizophrenia epidemiology insights, the total prevalent population was observed to be <\/span><strong>5,748,062 <\/strong><span>in 7MM in 2020.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>In 2020, the Schizophrenia diagnosed prevalent population was over <\/span><strong>3 million <\/strong><span>in 7MM.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Among the EU5 countries, <strong>Germany<\/strong> has the highest Schizophrenia diagnosed prevalent population while <strong>Spain<\/strong> had the lowest in 2020.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Men had the majority of Schizophrenia cases than women in the US and EU5, but had a lesser number of Schizophrenia cases in Japan as compared to women in 2020.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Schizophrenia pipeline drugs include <\/span><strong>Doria (risperidone ISM) (Rovi Pharmaceuticals Laboratories), Roluperidone (Minerva Neurosciences), Dexmedetomidine (BXCL501) (BioXcel Therapeutics), SEP363856 (Sunovion\/PsychoGenics), Pimavanserin (Acadia Pharmaceuticals), ALKS 3831 (Alkermes), Avisetron (AVN-211) (Avineuro Pharmaceuticals), BI 409306 (Boehringer Ingelheim), GWP42003-P (GW Research), KarXT (Karuna Pharmaceuticals), Evenamide (Newron Pharmaceuticals), Paliperidone Palmitate 6-Month(PP6M)<\/strong><span><strong> (Janssen Pharmaceutical)<\/strong> and others.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Key pharmaceutical companies such as <\/span><strong>Rovi Pharmaceuticals Laboratories, Minerva Neurosciences, BioXcel Therapeutics, Sunovion\/PsychoGenics, Acadia Pharmaceuticals, Alkermes, Avineuro Pharmaceuticals, Boehringer Ingelheim, GW Research, Karuna Pharmaceuticals, Newron Pharmaceuticals, Janssen Pharmaceutical,<\/strong><span> and others are developing therapies for Schizophrenia treatment.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>To find out more about schizophrenia, request sample @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/schizophrenia-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Schizophrenia Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Schizophrenia market report<\/strong><span> covers current treatment methods, developing medications, and market share of specific therapies, as well as the current and predicted market size of Schizophrenia in 7MM from 2018 to 2030. To gather the best of the opportunities and assess the underlying potential of the industry, the report also examines existing Schizophrenia treatment practice\/algorithm, market drivers, market barriers, and unmet medical needs.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Schizophrenia: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Schizophrenia is a severe mental illness that impairs one&#8217;s capacity to think effectively, manage emotions, make decisions, and interact with others. It&#8217;s a long-term medical condition that affects roughly 1% of the population of the United States. Schizophrenia is produced by a complex interplay of genetics and environmental circumstances, rather than by a single genetic mutation. While Schizophrenia affects 1% of the population, having a family history of psychosis considerably increases the risk.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Schizophrenia Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Schizophrenia Prevalent Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Schizophrenia Diagnosed Prevalent Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Schizophrenia Gender-Specific Diagnosed Prevalent Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Schizophrenia Age-Specific Diagnosed Prevalent Cases<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Schizophrenia Severity-Specific Diagnosed Prevalent Cases<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Schizophrenia Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Antipsychotics are the most common drugs used to treat Schizophrenia. They are often useful in treating positive Schizophrenia symptoms. Antipsychotic drugs affect everyone differently, so a patient may need to try many before finding the one that works best for them. The major options for Schizophrenia treatment include:<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Risperdal (risperidone)<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Abilify (aripiprazole)<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Invega Trinza\/sustenna<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Rexulti (brexpiprazole)<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Latuda (lurasidone hydrochloride)<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Caplyta (lumateperone)<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Schizophrenia Market<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>As per DelveInsight, the Schizophrenia market size was estimated to be <\/span><strong>USD 7,454.97 million<\/strong><span> in 7MM in 2020. The prevalence of Schizophrenia patients in the 7MM market is increasing, resulting in a larger Schizophrenia market. Patients and physicians have a high degree of information regarding the symptoms, diagnosis, treatment, and management of Schizophrenia due to the availability of healthcare resources. This will contribute to the future growth of the Schizophrenia market.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get more insights about schizophrenia management @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/schizophrenia-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Schizophrenia Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Schizophrenia Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Doria (risperidone ISM): Rovi Pharmaceuticals Laboratories<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Roluperidone: Minerva Neurosciences<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Dexmedetomidine (BXCL501): BioXcel Therapeutics<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>SEP363856: Sunovion\/PsychoGenics<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Pimavanserin: Acadia Pharmaceuticals<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>ALKS 3831: Alkermes<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Avisetron (AVN-211): Avineuro Pharmaceuticals<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>BI 409306: Boehringer Ingelheim<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>GWP42003-P: GW Research<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>KarXT: Karuna Pharmaceuticals<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Evenamide: Newron Pharmaceuticals<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Paliperidone Palmitate 6-Month (PP6M): Janssen Pharmaceutical<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Schizophrenia Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Increasing Awareness<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Growing Research and development<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Pipeline Advancement<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Long-acting Injectable Antipsychotics<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Schizophrenia Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Economic Burden<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Significant Side Effects of Approved Therapy<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Denial of illness<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Co-occurring medical conditions<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope for the Report<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Coverage: <\/strong><span>7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Study Period: <\/strong><span>2018-30<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Schizophrenia Key Companies: <\/strong><span>Rovi Pharmaceuticals Laboratories, Minerva Neurosciences, BioXcel Therapeutics, Sunovion\/PsychoGenics, Acadia Pharmaceuticals, Alkermes, Avineuro Pharmaceuticals, Boehringer Ingelheim, GW Research, Karuna Pharmaceuticals, Newron Pharmaceuticals, Janssen Pharmaceutical, among others.<\/span><span>&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Schizophrenia Key Pipeline Therapies: <\/strong><span>Doria (risperidone ISM), Roluperidone, Dexmedetomidine (BXCL501), SEP363856, Pimavanserin, ALKS 3831, Avisetron (AVN-211), BI 409306, GWP42003-P, KarXT, Evenamide, Paliperidone Palmitate 6-Month (PP6M),<\/span><span>and others.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Schizophrenia Segmentation: <\/strong><span>By Geography, Schizophrenia drugs<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis: <\/strong><span>Comparative and conjoint analysis of <\/span><span>&nbsp;Schizophrenia<\/span><span> emerging therapies<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Tools Used: <\/strong><span>SWOT Analysis<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Case Studies<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>KOL&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analyst&rsquo;s Views<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><span>&nbsp;<\/span><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"79\" \/>\n<col width=\"545\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span>1.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Key Insights<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>2.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Executive Summary of Schizophrenia<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>3.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia Market Overview at a Glance<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>4.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Disease Background and Overview: Schizophrenia<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>5.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia Case Reports<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>6.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia Epidemiology and Patient Population<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>7.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia United States Epidemiology<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>8.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia EU5 Epidemiology<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>9.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia Japan Epidemiology<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>10.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia Treatment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>11.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia Unmet needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>12.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia Marketed Drugs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>13.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia Emerging Drugs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>14.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Key Endpoints<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>15.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia: 7MM Market Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>16.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia United States Market Outlook<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>17.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia EU-5 Market Outlook<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>18.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia Japan Market Outlook<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>19.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia Key Market Forecast Assumptions<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>20.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia Market Drivers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>21.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia Market Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>22.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>SWOT Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>23.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Schizophrenia Reimbursement and Market Access<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>24.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>25.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>DelveInsight Capabilities<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>26.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Disclaimer<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>27.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>About DelveInsight<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>For rich insights into Healthcare and Pharmaceutical News, visit <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/sciatica-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Sciatica Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get comprehensive historical and forecast analysis of <\/span><span>Sciatica<\/span><span> Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as <\/span><strong>Scilex Holding Company, Seikagaku Corporation, Sollis Therapeutics, SpineThera, Kolon Life Science, Teijin America,&nbsp;<\/strong><span>among others.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.&nbsp;<\/span>&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=schizophrenia-pipeline-possesses-potential-drugs-in-mid-stage-developments-to-be-launched-in-the-upcoming-years\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=schizophrenia-pipeline-possesses-potential-drugs-in-mid-stage-developments-to-be-launched-in-the-upcoming-years\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Schizophrenia Market The growing prevalence of Schizophrenia patients in the 7MM market has resulted in an increase in Schizophrenia market size. DelveInsight&rsquo;s Schizophrenia market report provides an in-depth understanding of Schizophrenia, historical and forecasted epidemiology, and Schizophrenia market trends in &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/schizophrenia-pipeline-possesses-potential-drugs-in-mid-stage-developments-to-be-launched-in-the-upcoming-years_551539.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-551539","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/551539","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=551539"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/551539\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=551539"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=551539"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=551539"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}